GSK signed a deal worth up to $2.5 billion for ABL Bio's neuroscience technology. And more. 1. Congressional commission urges $15B, more action to maintain US biotech advantage over China The U.S ...

Neuroscience isn't currently one of the top strategic R&D priorities at GSK, but a new alliance with ABL Bio adds to the sense that its focus may be shifting. The UK-headquartered pharma group is ...

ABL Bio previously entered into a global licensing agreement with GSK to develop treatments for neurodegenerative diseases. "ACIP recommends GSK’s RSV vaccine for at-risk adults 50 to 59" was ...

ABL Bio previously entered into a global licensing agreement with GSK to develop treatments for neurodegenerative diseases. "ACIP recommends GSK’s RSV vaccine for at-risk adults 50 to 59" was ...

Learn about April 2025’s top biotech deals, featuring major collaborations in bispecific antibodies, protein therapies, and ...

The Swiss firm says it will use the funds to engineer a commercial-scale plant. GSK has teamed up with ABL Bio for the start-up’s Grabody-B technology, which is meant to help drugs cross the ...

Neuroscience isn't listed as one of the top R&D priorities at GSK, but a new alliance with ABL Bio adds to the sense that its focus may be shifting. Web editor Nicole Raleigh speaks with Rob ...

ABL Bio Inc., a South Korean biotech company, will license out its proprietary blood-brain barrier shuttle platform, called the Grabody-B, to UK-based pharmaceutical giant GSK plc in a deal expected ...

including the US, Japan and Europe. ABL Bio previously entered into a global licensing agreement with GSK to develop treatments for neurodegenerative diseases.